Singapore's Nanyang Biologics to list on Nasdaq amid Trump's pharma tariffs.

Nvidia will invest $2 billion in Lancium and commit an additional $1 billion as Lancium secures more planned power capacity, The Information reported. The deal values Lancium and its land and grid connections at about $10 billion enterprise value, and gives Nvidia about a 20% stake. The article also cites AWS efforts to cut CPU waste and a new AI research startup co-founded by Jeff Dean.

KBR said it secured a $208 million U.S. Army cost-plus-fixed-fee task order under OASIS+ for support tied to the TAGM portfolio, including Hellfire, JAGM, Javelin and TOW, plus Hydra rockets and Long-Range Precision Munitions. Work spans engineering, prototyping, modernization, foreign military sales and logistics across the weapons lifecycle.

Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.

Ouster, Inc. (Nasdaq: OUST) said Econolite received a Utah Department of Transportation expansion contract to deploy Ouster BlueCity at an additional 160 intersections statewide. The rollout uses Ouster’s OS1 Max Rev8 digital lidar, with up to 500-foot advance detection and native color lidar. Ouster said the total contracted footprint is nearly 300 intersections in Utah.

Simply Wall St reports MDA Space (TSX:MDA) secured an expanded role in Canada’s defence and communications programs, including a CAD 474 million increase to its Telesat Lightspeed satellite contract and prime contractor duties for the Enhanced Satellite Communications Project – Polar. The company also reported higher quarterly sales and opened its CHORUS mission control centre in Québec, expanding backlog and long-cycle government revenue.

Jim Cramer reiterated a triple buy call on Hinge Health (HNGE) on “Mad Money” Aug. 11. The stock hit a new all-time high of $93.13 on Aug. 10 and is up about 85.83% YTD, per Yahoo Finance. Hinge reported Q2 2026 revenue of $213 million (+53% YoY), free cash flow of $99.6 million, and raised FY guidance to $856-$860 million. It also agreed to a $105 million cash acquisition (Cylinder Health) to expand into GI care.